For all the troubles surrounding the Thousand Oaks-based biotech company, shares rose 2.3 percent today (on a day when the Dow picked up around half a percent). Actually, Amgen stock has been in rally mode since hitting a 52-week low of $55.13 on March 29. Today it closed at $57.64, which may not sound like such a leap if it weren't for the recent batch of really bad news. That included today's announcement from the National Kidney Foundation about plans to cut its recommended target for hemoglobin levels in kidney disease patients - a move that could hurt sales of Amgen's anemia drugs. And more bad news might be on the way: Amgen will be releasing another much-anticipated study later this month. Earnings will be delayed a few days so that the study comes out at the same time. So what gives? "We are not in a crisis, that's for sure," CEO Kevin Sharer told the NYT's Andrew Pollack. That's apparently the view of some investors who apparently consider this to be one of those good buying opportunities.
More by Mark Lacter:American-US Air settlement with DOJ includes small tweak at LAX
Socal housing market going nowhere fast
Amazon keeps pushing for faster L.A. delivery
Another rugged quarter for Tribune Co. papers
How does Stanford compete with the big boys?
Those awful infographics that promise to explain and only distort
Best to low-ball today's employment report
Further fallout from airport shootings
Crazy opening for Twitter*
Should Twitter be valued at $18 billion?
Recent stories:Siri versus Hawaiian pidgin (video)
Letter from Down Under: Welcome to the Homogenocene
One last Florida photo
Signs of Saturday: No refund
'I Am Woman,' hear them roar
New at LA Observed
On the Politics Page
Go to Politics
Sign up for daily email from LA Observed